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Delayed graft function (DGF) often occurs in kidney
transplants from deceased donors. We wanted to provide
studies giving more accurate non-invasive tests for acute
rejection (AR). Using real-time PCR, we examined the
expression of cytolytic molecules such as perforin, granzyme
B, and fas-ligand along with serpin proteinase inhibitor-9. We
also measured the expression of FOXP3, a characteristic gene
of T-regulatory cells known to be involved in AR. These
studies were conducted on peripheral blood monocytes,
urinary cells, and 48 surveillance kidney biopsies taken from
a total of 35 patients with DGF. Of these patients, 20 had a
histopathological diagnosis of AR, whereas other 28 had
characteristics of acute tubular necrosis (ATN). Expression of
cytolytic and apoptotic-associated genes in the biopsy tissue,
peripheral blood leukocytes, and urinary cells was
significantly higher in patients with AR than that in patients
with ATN. Diagnostic parameters associated with FOXP3
gene expression were most accurate in peripheral blood
leukocytes and urine cells with sensitivity, specificity, positive
and negative predictive values, and accuracy between 94 and
100%. Our study shows that quantification of selected genes
in peripheral blood leukocytes and urinary cells from renal
transplant patients with DGF may provide a useful and
accurate non-invasive diagnosis of AR.
Kidney International (2008) 73, 877–884; doi:10.1038/sj.ki.5002795;
published online 23 January 2008
KEYWORDS: kidney transplantation; perforin; fas-ligand; FOXP3; delayed
graft function; acute rejection
Although acute rejection (AR) has had a decreasing incidence
over the last decade, it is still a relevant problem in kidney
transplantation.1,2 Delayed graft function (DGF), which often
occurs after deceased-donor kidney transplantation, may last
a few days or weeks. It is associated with an increased
incidence of AR and produces detrimental effects on patient
and graft survival.3–7 This condition is usually defined by the
need for dialysis in the first week after transplantation, and
during its course, the diagnosis of AR is based upon the
histological analysis of graft samples obtained by surveillance
biopsies.8
In the last decade, molecular biology techniques such as
the reverse transcription-PCR provided new opportunities
for the development of non-invasive and more accurate
diagnostic tools for the analysis of genes associated with acute
and chronic rejection expressed in kidney tissue and
peripheral blood leukocytes.9–13 Genes that participate in
the cytolytic attack to the graft cells and those involved in cell
death through apoptotic mechanisms, such as perforin,
granzyme B, and fas-ligand, were studied as non-invasive
diagnostic markers of AR and led to a better understanding
of the processes involved in AR and subclinical AR.9,14
The real-time PCR (RT-PCR) is a more accurate and
reproducible technique that further contributed to the precise
mRNA expression analysis and the quantification of genes
involved in transplant rejection, which in turn allowed the
study of a variety of new possible molecular markers of
rejection.15–19 Among them is the serpin proteinase inhibitor-9
(PI-9), a naturally occurring endogenous blocker of gran-
zyme B, whose elevated levels of expression in cytolytic
T lymphocytes suggest the possibility of ongoing AR.20–22
More recently, the FOXP3 gene (X-linked forkhead/winged
helix transcription factor), predominantly found in CD4þ /
CD25þ regulatory T cells, was measured in urinary cells and
proved to be an accurate marker of AR as well as a reliable
predictor of responsiveness to corticosteroids.23
The fact that an accurate non-invasive diagnosis of AR
might be found by measuring the mRNA of selected genes in
peripheral blood leukocytes and urinary cells in patients with
DGF, thereby obviating or diminishing the need for
surveillance biopsies, is an exciting prospect. This study was
undertaken to verify the hypothesis that it is possible to
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2008 International Society of Nephrology
Received 11 April 2007; revised 30 October 2007; accepted 13
November 2007; published online 23 January 2008
Correspondence: RC Manfro, Division of Nephrology, Hospital de Clı´nicas
de Porto Alegre, 2350 Ramiro Barcelos Street, Room 2030, Porto Alegre, RS
90035-003, Brazil. E-mail: rmanfro@hcpa.ufrgs.br
Kidney International (2008) 73, 877–884 877
diagnose AR in kidneys with DGF based on mRNA
quantification, in urine and/or peripheral blood, of genes
that act as markers or that are mechanistically involved in the
AR process of kidney allografts.
RESULTS
From January 2004 to October 2006, 165 patients received
kidney transplants in our unit. The 35 patients who had DGF
for a period of at least 7 days and who had undergone a graft
biopsy during the DGF period, as well as 30 comparator
patients, were included in the study. Table 1 shows the main
demographic data of the groups. Sampling was predomi-
nantly constituted of biological materials obtained from
kidney transplants harvested from deceased donors, with a
higher proportion of men in all groups. No statistically
significant differences were observed between the groups with
reference to age, gender, and donor type distributions
(analysis of variance, Dunnett’s test, P40.05). There were
no statistically significant differences in time intervals
between the transplant and the moment of biopsy in the
group of patients with acute tubular necrosis (ATN) and the
comparator group with biopsies considered as normal
(NOR), as compared to the group with histopathological
diagnosis of AR (analysis of variance, Dunnett’s test,
P40.05). The mean time intervals in the group with
calcineurin inhibitor-induced nephrotoxicity (CIN) and in
the group with chronic allograft nephropathy (CAN) were
significantly higher than that in the AR group (analysis of
variance, Dunnett’s test, Po0.001). The mean time intervals
after the transplant in patients of the NOR group were
significantly lower than those of the CIN group (P¼ 0.015)
and CAN group (Po0.001) (Table 1).
Forty-eight surveillance biopsies were collected from 35
patients with DGF, 20 of which presented with histopatho-
logical features of AR and 28 with histopathological diagnosis
of ATN. The time for the diagnosis of AR ranged from 7 to 55
days (mean 21.4±15.6 days, median 14.5 days). According to
the Banff classification,24 three cases were classified as
borderline, eight as type IA, six as type IIA, and three as
type III. C4d deposition in peritubular capillaries was present
in one case. Serum creatinine levels did not differentiate AR
from ATN (5.32±3.36 versus 5.96±2.01 mg per 100 ml,
respectively; P¼ 0.784). Creatinine levels in the comparator
groups were as follows: CIN: 3.08±1.16 mg per 100 ml; CAN:
4.65±1.95 mg per 100 ml; and NOR: 1.69±0.4 mg per
100 ml. The group of patients with normal biopsies had a
lower mean serum creatinine than the groups with AR
(Po0.001), ATN (Po0.001), and CAN (P¼ 0.014). No
statistically significant differences were observed in the
comparison of the mean serum creatinine between the
NOR and the CIN groups (P¼ 0.625).
Perforin, granzyme B, and fas-ligand gene expression
levels in kidney tissue, peripheral blood leukocytes, and
urinary cells are shown in the box plots presented in Figure 1.
Similarly, FOXP3 and PI-9 results are displayed in Figure 2.
For all genes analyzed, significantly higher quantities of
transcripts were present in AR than that in ATN. These
findings were observed in kidney tissue, peripheral blood
leukocytes, and urinary cells. Similarly, in all compartments,
the normalized quantities of the studied genes were
significantly higher in samples of patients with DGF and
AR than that of patients of the comparator groups. The only
exception occurred with the PI-9 gene quantification, in
which the amount observed in AR did not differ from the
amount present in the group of patients with CIN (Figure 2).
Table 2 shows Spearman’s correlation coefficients between
the genes in the different compartments. Strong and
significant correlations were observed between the quantifi-
cations in tissue, blood, and urine for all genes. Although all
correlations reached statistical significance, those observed
for the FOXP3 gene were the strongest, with correlation
coefficient values of 0.95 or higher.
The areas under the curves and cutoff points obtained
from receiver-operating characteristic curve analyses, and the
Table 1 | Demographic data of studied groups and comparators
Groups (number of patients)
DGF (35) Comparators (30)
Histopathological diagnoses (number of samples) AR (20) ATN (28) CIN (8) CAN (12) NOR (10)
Age (years; mean±s.d.)a 41±13 47±10 43±11 47±12 47±08
Gender (male/female)b 8/6 15/6 03/05 07/05 07/03
Transplant number (1st, 2nd) 14/0 20/1 6/2 9/3 10/0
Donor (living/deceased)b 3/11 2/19 01/07 01/11 01/09
Cold ischemia time (hours; mean±s.d.)a 14.4±8.5 16.8±6.6 12.4±8.8 16.9±7.2 16.8±7.8
Time to biopsy (days; mean±s.d.)a 21±15 21±14 225±212c 269±213c 74±8d,e
Donors’ CMV status (positive/negative)b 14/0 20/1 8/0 12/0 10/0
Recipients’ CMV status (positive/negative)b 13/1 20/1 8/0 12/0 9/1
Panel reactive antibodies (%; mean±s.d.)a 19.4±33.6 2.20±11.0f 0±0 15.6±26.9 8.4±22.6g
HLA mismatches (A, B, DR; mean±s.d.)a 3.07±1.82 3.35±1.27 3.75±1.26 4.29±1.38 2.88±1.35
Serum creatinine (mg per 100 ml; mean±s.d.)a 5.32±3.36 5.96±2.01 3.08±1.16 4.65±1.95 1.69±0.4c,h
Induction (Thymoglobulin/Basiliximab) 3/11 0/21 0/4 2/6 1/6
ANOVA, analyses of variance; AR, acute rejection; ATN, acute tubular necrosis; CAN, chronic allograft nephropathy; CIN, calcineurin inhibitor-induced nephrotoxicity; CMV,
cytomegalovirus; DGF, delayed graft function; NOR, normal; s.d., standard deviation.
aANOVA with Dunnett’s test; bFisher’s exact test; cPo0.001 versus AR and ATN; dPo0.02 versus CIN; ePo0.001 versus CAN; fPo0.01 versus AR; gPo0.05 versus AR; hPo0.02
versus CAN.
None of the other comparisons showed statistically significant differences.
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diagnostic parameters for AR of the gene quantifications
in peripheral blood leukocytes and urinary cells are all
presented in Tables 3 and 4, respectively. In peripheral blood,
all genes showed a good diagnostic performance. However,
the FOXP3 gene analysis showed higher accuracy than the
other genes evaluated (Table 3). In the analysis of diagnostic
parameters derived from gene quantification in urinary
cells, again the FOXP3 gene was the most precise, showing
absolute accuracy, whereas the PI-9 gene showed lower
performance, mainly because of its low specificity and
positive predictive values.
DISCUSSION
In studies that did not include patients with DGF, increased
amounts of gene transcripts of cytotoxic molecules, PI-9 and
FOXP3 have been found in mRNA obtained from kidney
tissue, peripheral blood cells, and urinary cells of renal
transplant patients with acute graft rejection.10–12,25 The
better standardization and reproducibility of the RT-PCR
method allowed for a significant progress in gene quantitative
transcriptional profiling. By using this technique, it is
possible to monitor intragraft inflammatory events and
detect AR episodes,15,17,26 determine their diagnosis in
advance,21,27 predict treatment responsiveness,18 and differen-
tiate them from urinary tract infections.28 However, the
usefulness of this method has not been properly evaluated
during DGF, a situation in which a non-invasive method of
adequate accuracy would be a cost-effective aid to clinical
management.
In this study, evaluating patients with DGF, mRNA
quantification by RT-PCR showed that the studied genes
showed increased expression in AR in all compartments
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Figure 1 | mRNA levels of perforin, granzyme B, and fas-ligand in kidney tissue, peripheral blood leukocytes, and urinary cells
according to the histological diagnosis. The box-plot representation shows the medians and the percentile values 10, 25, 75, and 90
for the quantification levels of normalized mRNA (2DDCT ). b-Actin quantification was used for normalizing the mRNA amounts present in
kidney tissue and peripheral blood leukocytes. Cyclophilin quantification was used for mRNA normalization in urinary cells. The expression
levels of Per, GzB, and FasL genes were significantly higher in patients with AR as compared to patients with ATN and to the control
groups: CIN, CAN, and NOR in kidney tissue, peripheral blood, and urinary cells. P-values are the lowest of the comparisons between each
compartment per gene. Per, perforin; GzB, granzyme B; FasL, fas-ligand; AR, acute rejection; ATN, acute tubular necrosis; CIN, calcineurin
inhibitor-induced nephrotoxicity; CAN, chronic graft nephropathy; and NOR, normal.
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studied. In the evaluation of the mRNA from peripheral
blood leukocytes, the analysis of diagnostic parameters
showed that all genes produced accurate parameters.
However, FOXP3 produced the best diagnostic parameters
by having higher specificity, positive predictive value, and
overall accuracy. FOXP3 mRNA in peripheral blood leuko-
cytes has been shown to correlate with the amount of
CD4þ /CD25þ T cells in peripheral blood of kidney
transplant patients.29 During AR, elevated FOXP3 mRNA
within the graft, in urinary cells, and in peripheral blood cells
suggests the development of a host immune regulatory graft
protective response. It is conceivable that the increased
amount of FOXP3 mRNA found in patients with rejecting
grafts mirrors an active response to graft-damaging effector
T cells, showing that the immune response to the graft cells
possesses both cyto-destructive and cyto-protective compo-
nents.29,30 Alternatively, as suggested in recent studies with
human cells, it is also possible that the elevated levels of
FOXP3 mRNA found in the group of patients with rejection
represent an activation-induced phenomenon that might
not be involved in regulatory activities of the immune
response.31,32
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Figure 2 | mRNA levels of PI-9 and FOXP3 in kidney tissue, peripheral blood leukocytes, and urinary cells according to the histological
diagnosis. The box-plot representation shows the medians and the percentile values 10, 25, 75, and 90 for the quantification levels of
normalized mRNA ((2DDCT ). b-Actin quantification was used for normalizing the mRNA amounts present in kidney tissue and peripheral blood
leukocytes. Cyclophilin quantification was used for mRNA normalization in urinary cells. The expression level of PI-9 was higher in patients with
AR as compared to patients with ATN and to the control groups CAN and NOR in the three compartments. P-values are the lowest in
comparisons in each compartment. *There was no significant difference in PI-9 gene quantification in urinary cells when comparing the AR and
CIN groups (P40.05). The levels of FOXP3 were always higher in AR cases as compared to all other groups. PI-9¼ serpin proteinase inhibitor-9;
FOXP3¼X-linked forkhead/winged helix transcription factor-3.
Table 2 | Spearman’s correlation coefficients of gene quantifications at the different compartments
Compartments
Peripheral blood–tissue Urinary cells–tissue Urinary cells–peripheral blood
Gene Correlation coefficient P-value Correlation coefficient P-value Correlation coefficient P-value
Per 0.939 o0.001 0.885 o0.001 0.929 o0.001
GzB 0.822 o0.001 0.883 o0.001 0.825 o0.001
FasL 0.601 o0.001 0.668 o0.001 0.842 o0.001
PI-9 0.767 o0.001 0.540 o0.001 0.707 o0.001
FOXP3 0.976 o0.001 0.980 o0.001 0.950 o0.001
FasL, fas ligand; FOXP3, X-linked forkhead/winged helix transcription factor-3; GzB, granzyme B; Per, perforin; PI-9, serpin proteinase inhibitor-9.
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The evaluation of mRNA levels in peripheral blood
leukocytes of patients with kidney transplants can be a
valuable tool for the diagnosis of rejection, as these analyses
do not depend on the urine production by the graft. In
previous studies in which mRNA was quantified by reverse
transcription competitive PCR, Vasconcellos et al.12 demons-
trated that in patients without DGF, the mRNA evaluation of
peripheral blood may produce proper diagnostic parameters
for AR.
The mRNA analyses of urine-sediment cells of kidney
transplant patients are interesting, given that under most
circumstances the lymphocytes present in urine have
trafficked through the kidney, and therefore the status of
these cells might accurately reflect the status of graft-
infiltrating lymphocytes. However, this will depend on the
urine production by the graft, which can be a limitation in
anuric ATN. Another limitation is the possibility of analyzing
urine produced by the native kidney and not by the graft. In
this study, it was not possible to have a proper urine sample
for analysis in 20% of the cases, but when urine was available,
accurate diagnostic parameters were achievable. The evalua-
tions of mRNA amounts amplified from urinary cells resulted
in diagnostic parameters that were similar to those found in
the peripheral blood evaluation. Interestingly, the analysis of
FOXP3 mRNA amounts in the urinary cells allowed for
perfect diagnostic accuracy. In the FOXP3 mRNA analysis,
our data of patients with DGF were comparable to the
description found in a recent study by Muthukumar et al.,23
where the levels of FOXP3 and perforin in urinary cells were
significantly higher in patients with AR, as compared to
groups with histological diagnoses of chronic graft nephro-
pathy and transplants with stable function.
In the analyses of both peripheral blood and urinary cells,
the molecular mRNA quantifications allowed for the
differentiation of AR from other clinical situations. Such
differentiations had already been shown in urinary cells in
other studies.21,23,27,33,34 However, evaluations in patients
with DGF are quite limited. Only two studies reported this
evaluation in a rather restricted number of patients. By using
the competitive PCR method, Li et al.25 observed that in 9
out of 11 patients with DGF, the perforin and granzyme B
expression levels were significantly higher in patients with
AR. Using the RT-PCR technique, Yannaraki et al.35 evaluated
five patients with DGF and reported that the detected
amounts of perforin, granzyme B, and fas-ligand were also
increased in patients with AR.
Amounts of mRNA of other genes have been evaluated for
the diagnosis of AR. Urinary levels of CD103 mRNA were
described by Ding et al.27 Granulysin expression showed a
strong predictive value for rejection episodes early after
kidney transplantation.17 The chemokine interferon-induci-
ble protein 10 mRNA expression analysis allowed for the
differentiation between urinary tract infections and cytome-
galovirus infections and AR.34 Evaluation of interleukin-4
and tumor necrosis factor-a genes revealed the possibility of
diagnosing rejection before the appearance of its clinical and
laboratorial signs.36 The analyses of the above-mentioned
genes are certainly worth performing in the DGF setting.
However, two recent studies did not find mRNA
evaluations to be useful for the diagnosis of AR in renal
transplantation.35,37 In the first study, Yannaraki et al.35
evaluated the expression of the perforin, granzyme B, and
fas-ligand genes and demonstrated that their levels were
increased in AR, but a similar profile was also present in
other clinical situations, such as cytomegalovirus infections,
urinary infections, and DGF, the latter having been evaluated
in a restricted number of patients. The other study, using a
conventional semiquantitative PCR technique, suggested that
the expression of perforin and fas-ligand genes in kidney
tissue could predict the diagnosis of AR, but the expression of
these genes in peripheral blood did not correlate with the
histopathological diagnosis of AR. The discrepancy between
these results and many others in the literature, including
ours, is probably related to methodological issues such as
sample size and factors related to urine sampling that might
have affected other stages of the PCR. Recommendations for
the collection and storage of urinary cells were proposed by
Medeiros et al.,38 suggesting the importance of the utilization
of an RNA stabilization solution.
As limitations of this study, it must be acknowledged that
the samples of patients with CIN, CAN, and normal
transplant kidneys were not obtained from patients with
Table 3 | Cutoff points and diagnostic parameters, in
percentage, of molecular quantifications to the AR diagnosis
in peripheral blood of patients with DGF
Gene AUC (CI 95%) Cutoff point Se Sp PPV NPV A
Per 0.881 (0.766–0.966) 0.85 100 75 77 100 86
GzB 0.941 (0.869–1.013) 0.05 88 90 88 90 89
FasL 0.935 (0.852–1.019) 0.15 89 94 90 95 92
PI-9 0.935 (0.850–1.021) 0.20 88 90 88 90 88
FOXP3 0.954 (0.871–1.037) 1.85 94 95 94 95 95
95% CI, 95% confidence interval; A=accuracy (% of cases correctly classified); AR,
acute rejection; AUC, area under the curve; DGF, delayed graft function; FasL, fas
ligand; FOXP3, X-linked forkhead/winged helix transcription factor-3; GzB, granzyme
B; NPV, negative predictive value; Per, perforin; PI-9, serpin proteinase inhibitor-9;
PPV, positive predictive value; Se, sensitivity; Sp, specificity.
Table 4 | Cutoff points and diagnostic parameters, in
percentage, of molecular quantifications for the AR diagnosis
in urinary cells of patients with early graft function
Gene AUC (CI 95%) Cutoff point Se Sp PPV NPV A
Per 0.917 (0.788–1.046) 0.22 100 86 86 100 92
GzB 0.851 (0.692–1.011) 0.20 83 86 83 86 85
FasL 0.887 (0.763–1.011) 0.07 100 64 71 100 81
PI-9 0.875 (0.745–1.005) 0.024 92 64 67 90 76
FOXP3 1.000 (1.000–1.000) 2.2 100 100 100 100 100
95% CI, 95% confidence interval; A, accuracy (% of cases correctly classified); AR,
acute rejection; AUC, area under the curve; DGF, delayed graft function; FasL, fas
ligand; FOXP3, X-linked forkhead/winged helix transcription factor-3; GzB, granzyme
B; NPV, negative predictive value; Per, perforin; PI-9, serpin proteinase inhibitor-9;
PPV, positive predictive value; Se, sensitivity; Sp, specificity.
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DGF. Although chronic graft nephropathy is not an expected
diagnosis during DGF, CIN may occur early after transplan-
tation and could play an important role in delaying
functional graft recovery.4 It is also important to emphasize
that a more appropriate control group would have been
found by obtaining biopsies, blood, and urine from patients
without DGF at time points similar to those obtained from
patients with DGF. However, obtaining early biopsies from
well-functioning grafts during the first post-transplant
month is not an established practice and may raise ethical
issues due to the risks imposed by doing it.
The findings of this study allowed for the conclusion that
the analysis of mRNA quantifications of the genes involved in
the alloimmune response in patients with DGF, both from
peripheral blood leukocytes and from urine-sediment cells,
provides an accurate molecular signature for the diagnosis of
AR. The validation of these results in a multicenter,
longitudinal study and possible sophistications of employed
techniques may enable the molecular evaluations to replace
or reduce the need for surveillance biopsies in kidney
recipients during the DGF period. Besides, the combined
analyses of different genes, perhaps in different compart-
ments, may lead to even more precise diagnoses in this
difficult clinical situation.
MATERIALS AND METHODS
Patients and sample collection
Primary renal disorders leading to end-stage renal failure were as
follows: hypertensive glomerulosclerosis in 14 (8 with DGF)
patients; chronic glomerulonephritis in 10 (6 with DGF) patients;
obstructive uropathy and chronic pyelonephritis in 7 (3 with DGF)
patients; diabetic nephropathy, adult polycystic kidney disease, and
systemic lupus erythematosus in 5 (4, 3, and 2 with DGF,
respectively) patients for each condition; and undetermined in 19
(9 with DGF) patients.
Patients with transplanted kidneys with DGF, defined by the need
for dialysis during the first week after transplantation, were
submitted to surveillance biopsies every 7–10 days until kidney
function was recovered or graft was lost. Vascular, urological, or
infectious reasons for graft dysfunction were ruled out by Doppler
ultrasound, nuclear scans, and urine cultures before the biopsies were
performed. Immediately before each biopsy, peripheral blood and
sterile urine samples were collected from patients with diuresis. Two
core fragments were obtained in the biopsies. The kidney biopsies
were performed through ultrasonography guidance, using a semi-
automatic gun with a 16-G needle. One and a half fragments were
used for histological analyses and half a fragment was immediately
frozen in liquid nitrogen and maintained at 70 1C. Immediately
after the collection, the blood and urinary cells were isolated and
frozen for later RNA extraction. Slide evaluation was performed by a
kidney pathologist who was unaware of the clinical data. The Banff-
97 classification was used for the histopathological diagnoses.19
Patients with DGF were classified as having either ATN or AR.
Patients with histopathological diagnoses of CIN (n¼ 8), chronic
graft nephropathy (CAN; n¼ 12), and normal transplanted kidney
(NOR; n¼ 10) were used as comparators. Patients in the comparator
groups were randomly selected among patients who had biopsies
performed to elucidate graft dysfunction or as protocol biopsies, and
they all had blood and urine collection at the time of their biopsies.
In the DGF group, corticosteroids combined with cyclosporin or
tacrolimus and mycophenolate (mofetil or sodium) were used as
immunosuppressive therapy for all patients. Induction with
polyclonal antilymphocyte antibodies (Thymoglobulin) was per-
formed in three patients considered as having high immunological
risk, whereas all the other patients in the DGF group received
interleukin-2 anti-receptor antibodies (Basiliximab). Among the
comparators, 11 patients received triple therapy without antibody
induction, three received antilymphocyte antibodies (Thymoglobu-
lin), and 16 were induced with interleukin-2 anti-receptor
antibodies (Basiliximab).
The study was approved by the Research Ethics Committee of the
Hospital de Clı´nicas de Porto Alegre, accredited by the National
Research Council of the Brazilian Ministry of Health, and registered
at the Office for Human Research Protections—OHRP-USDHHS
(Institutional Review Board—IRB 00000921).
RNA extraction
Graft fragments were defrosted, macerated, and processed for the
RNA extraction, using the QIAamp RNA Blood mini kit (Qiagen
Inc., Chatsworth, CA, USA) method, according to the manufac-
turer’s instructions. Peripheral blood was collected in tubes
containing EDTA and the cells were separated with an erythrocyte
lysis buffer. Urinary cells were obtained by centrifugation at 500 g for
20 min. The floating material was discarded and cell pellets were
resuspended in a phosphate-buffered saline solution, centrifuged
again for 10 min, and stored at 70 1C. RNA was extracted from cell
pellets and isolated from peripheral blood and urine-sediment cells
by using the same method as for the renal tissue. RNA quality was
assessed by evaluating the optical density (OD) 260/280 ratio, and
only RNA samples with OD ratio higher than 1.7 were analyzed,
provided that a sufficient amount was available. In 10 occasions
(21%), urine samples were either not available (six occasions,
12.5%) or did not provide enough RNA for analyses (four occasions,
8.3%).
mRNA quantification
The expression of each gene was analyzed by using the relative
quantification technique through RT-PCR employing the ABI Prism
7000 (Applied Biosystems, Foster City, CA, USA) detection system.
Gene expression assays consist of a mixture of primers and TaqMan
MGB (minor groove binding) probes at 360 mM concentrated 20
times. Primers were designed based upon the identification of target
sequences at the gene bank. The sequences utilized had already been
designed, tested, and previously validated by the manufacturer, and
all primers utilized are intron-spanning to avoid genomic DNA
amplification (Gene Expression Assays/Custom primers and probes;
Applied Biosystems). The fluorescent dyes used as markers of the
probes were 6-carboxyfluorescein (FAM) as reporter (at 50) and
6-carboxytetramethyl rhodamine (TAMRA) as quencher (at 30). The
following genes were analyzed: perforin (Pf; ID: 65328531A;
GenBank reference: 5551), granzyme B (GB; ID: Hs 00188051_m1;
GenBank reference: 3002), fas-ligand (FasL; ID: Hs 00181225_m1;
GenBank reference: 356), PI-9 (ID: Hs 00244603_m1; GenBank
reference: 5272), and FOXP3 (ID: Hs 00203958_m1; GenBank
reference: 50943). The endogenous molecular controls used were
b-actin (PN 4310881E) for biopsy and peripheral blood samples,
and cyclophilin (PN 4310883E) for urine samples (TaqMan PDAR
Endogenous Control). To have equivalent amounts of mRNA in
each reaction, sample normalization was achieved by using the
controls described above.
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The reactions were made in duplicates using the TaqMan EZ RT-
PCR (PN N808-0235) (Applied Biosystems) kit, according to the
following protocol: 5.0 ml of 5 TaqMan EZ buffer, 3.0ml of
manganese acetate (25 mM), 0.75ml of dATP (10 mM), 0.75ml of
dCTP (10 mM), 0.75ml of dGTP (10 mM), 0.75 ml of dUTP (20 mM),
1.0ml of recombinant Thermus thermophilus DNA polymerase
(2.5 U/ml), 0.25 ml of AmpErase UNG (1 U/ml), and pure water to
reach a volume of 23 ml. For each reaction, 1 ml of primers and
probes (20 ) and 1 ml of RNA were added to this mixture, reaching
a final volume of 25 ml. The cycling program consisted of heating at
50 1C for 2 min, 60 1C for 30 min, followed by heating to 95 1C for
5 min and 40 cycles using the temperatures of 94 1C for 20 s and
62 1C for 60 s. The intrasample variability of all the RT-PCR
performed was always lower than 1%. For all duplicates analyzed,
the mean intrasample variability percentage was 0.038±0.02.
In the DGF group, 28 patients had one set of analyses, three
patients had two sets, two patients had three sets, and two patients
had four sets of analyses. The analyses of amplified products were
performed through the relative quantification method (2DDCT ,
which describes alterations to the target gene expression concerning
a reference sample.39
Statistical analyses
Data are presented as absolute numbers, mean±s.d., or percentages.
Gene quantifications are shown as box-plot representations.
Continuous variables with normal distributions were evaluated
using the analysis of variance followed by the Dunnett’s test. The
mRNA levels were analyzed using the Kruskal–Wallis test with all five
diagnostic groups. Dunn’s test was used for multiple comparisons
among the various groups. Mann–Whitney’s test was used for
comparisons between two groups. Fisher’s exact test was used for the
analyses of categorical variables. The correlations between the
mRNA levels with all genes were calculated by using Spearman’s
correlation test. Receiver-operating characteristic curves were
generated to find the best cutoff points for the diagnoses of AR.40
All analyses were performed by using the SPSS (Statistical Package
for the Social Sciences) program (version 14.0; SPSS Inc., Chicago,
IL, USA). The P-values were adjusted by using Finner’s method, and
the statistical significance level was established as Po0.05.
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